aTyr Pharma, Inc. (ATYR)
ATYR Stock Price Chart
Explore aTyr Pharma, Inc. interactive price chart. Choose custom timeframes to analyze ATYR price movements and trends.
ATYR Company Profile
Discover essential business fundamentals and corporate details for aTyr Pharma, Inc. (ATYR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
—
Employees
56.00
Website
https://www.atyrpharma.comCEO
Sanjay S. Shukla
Description
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
ATYR Financial Timeline
Browse a chronological timeline of aTyr Pharma, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 May 2026
Upcoming earnings on 11 Mar 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$0.16, while revenue estimate is $1.09M.
Earnings released on 7 Aug 2025
EPS came in at -$0.22 falling short of the estimated -$0.18 by -22.22%.
Earnings released on 7 May 2025
EPS came in at -$0.17 surpassing the estimated -$0.19 by +10.53%.
Earnings released on 13 Mar 2025
EPS came in at -$0.18 surpassing the estimated -$0.23 by +21.74%.
Earnings released on 7 Nov 2024
EPS came in at -$0.23 falling short of the estimated -$0.22 by -4.55%.
Earnings released on 13 Aug 2024
EPS came in at -$0.23 falling short of the estimated -$0.22 by -4.55%.
Earnings released on 2 May 2024
EPS came in at -$0.23 surpassing the estimated -$0.24 by +4.17%, while revenue for the quarter reached $235.00K , beating expectations by +540.90%.
Earnings released on 14 Mar 2024
EPS came in at -$0.25 falling short of the estimated -$0.24 by -4.17%.
Earnings released on 30 Sept 2023
EPS came in at -$0.20 surpassing the estimated -$0.23 by +13.32%, while revenue for the quarter reached $353.00K , missing expectations by -76.47%.
Earnings released on 30 Jun 2023
EPS came in at -$0.22 surpassing the estimated -$0.28 by +19.68%.
Earnings released on 31 Mar 2023
EPS came in at -$0.29 surpassing the estimated -$0.35 by +18.50%.
Earnings released on 31 Dec 2022
EPS came in at -$0.26 surpassing the estimated -$0.48 by +46.19%, while revenue for the quarter reached $10.39M , beating expectations by +2.81K%.
Earnings released on 29 Sept 2022
EPS came in at -$0.46 surpassing the estimated -$0.46 by +0.27%.
Earnings released on 29 Jun 2022
EPS came in at -$0.44 .
Earnings released on 30 Mar 2022
EPS came in at -$0.44 falling short of the estimated -$0.38 by -14.36%.
Earnings released on 30 Dec 2021
EPS came in at -$0.31 .
Earnings released on 29 Sept 2021
EPS came in at -$0.42 .
Earnings released on 30 Jun 2021
EPS came in at -$0.64 .
Earnings released on 31 Mar 2021
EPS came in at -$0.51 .
Earnings released on 31 Dec 2020
EPS came in at -$0.47 , while revenue for the quarter reached $2.05M .
Earnings released on 30 Sept 2020
EPS came in at -$0.68 , while revenue for the quarter reached $148.00K .
ATYR Stock Performance
Access detailed ATYR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.